当前位置：
X-MOL 学术
›
JAMA Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
JAMA Neurology ( IF 20.4 ) Pub Date : 2024-03-25 , DOI: 10.1001/jamaneurol.2024.0395 Guillaume Jouvenot 1, 2 , Guilhem Courbon 3 , Mathilde Lefort 4 , Fabien Rollot 5, 6, 7, 8 , Romain Casey 5, 6, 7, 8 , Emmanuelle Le Page 3, 9 , Laure Michel 3, 9 , Gilles Edan 3, 9 , Jérome de Seze 1, 2, 10 , Laurent Kremer 2, 10 , Kevin Bigaut 2, 10 , Sandra Vukusic 5, 6, 7, 8 , Guillaume Mathey 11, 12 , Jonathan Ciron 13 , Aurélie Ruet 14 , Elisabeth Maillart 15 , Pierre Labauge 16 , Hélène Zephir 17 , Caroline Papeix 18 , Gilles Defer 19 , Christine Lebrun-Frenay 20 , Thibault Moreau 21 , David Axel Laplaud 22, 23 , Eric Berger 24 , Bruno Stankoff 25 , Pierre Clavelou 26 , Eric Thouvenot 27 , Olivier Heinzlef 28 , Jean Pelletier 29 , Abdullatif Al-Khedr 30 , Olivier Casez 31 , Bertrand Bourre 32 , Philippe Cabre 33 , Abir Wahab 34 , Laurent Magy 35 , Jean-Philippe Camdessanché 36 , Ines Doghri 37 , Solène Moulin 38 , Haifa Ben-Nasr 39 , Céline Labeyrie 40 , Karolina Hankiewicz 41 , Jean-Philippe Neau 42 , Corinne Pottier 43 , Chantal Nifle 44 , Nicolas Collongues 1, 2, 10, 45 , Anne Kerbrat 3, 9, 46 ,
JAMA Neurology ( IF 20.4 ) Pub Date : 2024-03-25 , DOI: 10.1001/jamaneurol.2024.0395 Guillaume Jouvenot 1, 2 , Guilhem Courbon 3 , Mathilde Lefort 4 , Fabien Rollot 5, 6, 7, 8 , Romain Casey 5, 6, 7, 8 , Emmanuelle Le Page 3, 9 , Laure Michel 3, 9 , Gilles Edan 3, 9 , Jérome de Seze 1, 2, 10 , Laurent Kremer 2, 10 , Kevin Bigaut 2, 10 , Sandra Vukusic 5, 6, 7, 8 , Guillaume Mathey 11, 12 , Jonathan Ciron 13 , Aurélie Ruet 14 , Elisabeth Maillart 15 , Pierre Labauge 16 , Hélène Zephir 17 , Caroline Papeix 18 , Gilles Defer 19 , Christine Lebrun-Frenay 20 , Thibault Moreau 21 , David Axel Laplaud 22, 23 , Eric Berger 24 , Bruno Stankoff 25 , Pierre Clavelou 26 , Eric Thouvenot 27 , Olivier Heinzlef 28 , Jean Pelletier 29 , Abdullatif Al-Khedr 30 , Olivier Casez 31 , Bertrand Bourre 32 , Philippe Cabre 33 , Abir Wahab 34 , Laurent Magy 35 , Jean-Philippe Camdessanché 36 , Ines Doghri 37 , Solène Moulin 38 , Haifa Ben-Nasr 39 , Céline Labeyrie 40 , Karolina Hankiewicz 41 , Jean-Philippe Neau 42 , Corinne Pottier 43 , Chantal Nifle 44 , Nicolas Collongues 1, 2, 10, 45 , Anne Kerbrat 3, 9, 46 ,
Affiliation
A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.
中文翻译：
50 岁及以上非活动性多发性硬化症患者高效治疗的中断与继续治疗。
最近的一项随机临床试验得出结论，对于患有非活动性多发性硬化症 (MS) 的老年患者来说，停止中效治疗可能是一个合理的选择，但缺乏关于停止高效治疗 (HET) 的数据。在年轻患者中，停用那他珠单抗和芬戈莫德与疾病活动性反弹的风险相关。
更新日期：2024-03-25
中文翻译：
50 岁及以上非活动性多发性硬化症患者高效治疗的中断与继续治疗。
最近的一项随机临床试验得出结论，对于患有非活动性多发性硬化症 (MS) 的老年患者来说，停止中效治疗可能是一个合理的选择，但缺乏关于停止高效治疗 (HET) 的数据。在年轻患者中，停用那他珠单抗和芬戈莫德与疾病活动性反弹的风险相关。
京公网安备 11010802027423号